Approved for INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.. Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα. In vitro,…
Loading full data from Know Your Drugs Institute…